A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...

HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.

A common, non-invasive skin imaging technique can predict which melanoma patients face a higher risk of metastasis as accurately as current methods that require analyzing tumor samples after surgery.